Silvia Belloni, Cristina Arrigoni, Irene Baroni, Gianluca Conte, Federica Dellafiore, Greta Ghizzardi, Arianna Magon, Giulia Villa, Rosario Caruso
INTRODUCTION: Literature encloses numerous systematic reviews (SRs) on nonpharmacologic interventions for improving cancer-related fatigue (CRF). The effect of these interventions remains controversial, and the available SRs have not been synthesized yet. We conducted a systematic synthesis of SRs and meta-analysis to determine the effect of nonpharmacologic interventions on CRF in adults. MATERIAL AND METHODS: We systematically searched 4 databases. The effect sizes (standard mean difference) were quantitatively pooled using a random-effects model...
March 21, 2023: Seminars in Oncology
Laura Pala, Tommaso De Pas, Eleonora Pagan, Saverio Minucci, Chiara Catania, Nunzio Digiacomo, Emilia Cocorocchio, Daniele Laszlo, Antonio Di Muzio, Chiara Barigazzi, Erika Stucchi, Laura De Grandi, Sara Stucchi, Giuseppe Viale, Richard D Gelber, Vincenzo Bagnardi, Fabio Conforti
Available evidence suggests that in patients with advanced BRAF V600-mutant melanoma treated with the combination of BRAF and MEK inhibitors, gender could be associated with survival outcome. We performed a systematic review and meta-analysis of all randomized clinical trials (RCTs) testing the combination of BRAF and MEK inhibitors, to assess the interaction between treatment effect and patients' gender. We searched PubMed, MEDLINE, Embase, and Scopus, for phase II and III RCTs up to January 30, 2022. We included all RCTs that enrolled patients with BRAF V600-mutant advanced cutaneous melanoma and assessed combinations of BRAF and MEK inhibitors versus BRAF inhibitor monotherapy...
March 21, 2023: Seminars in Oncology
Naoki Kawakami, Hiroaki Saito, Susumu Takahashi, Shinpei Kajie, Rina Kato, Kazuhiro Shimaya, Yoko Wakai, Kazuhito Saito, Mai Sakashita
Immune checkpoint inhibitors (ICI) are widely used for the treatment of various malignant neoplasms. Interstitial lung disease is a well-known immune-related adverse event, however, ICI-induced airway disease remains under-recognized. Herein, we report two similar cases of pembrolizumab-induced tracheobronchitis presenting as persistent chronic cough and dyspnea. Blood tests revealed elevated C-reactive protein levels without eosinophilia. Spirometry demonstrated mild airflow obstruction. Computed tomography revealed diffuse thickening of the tracheobronchial walls and bronchiectasis predominantly in the lower lobes...
February 2, 2023: Seminars in Oncology
Irene Persano, Elena Parlagreco, Anna La Salvia, Marco Audisio, Marco Volante, Consuelo Buttigliero, Giorgio Vittorio Scagliotti, Maria Pia Brizzi
The simultaneous or metachronous occurrence of pancreatic neuroendocrine tumor (panNET) and renal cell carcinoma (RCC) may represent a rare coincidence or a manifestation of von Hippel-Lindau disease (VHL). These two malignancies share both radiological and cytopathological features, making the differential diagnosis very challenging. In this review, we collected all cases of concurrent diagnosis of localized panNET and RCC, with or without VHL, as reported in the literature to date. We aimed to provide an insight into the differential diagnosis between panNET and RCC pancreatic metastasis with a focus on the optimal therapeutic algorithm depending on the diagnosis...
February 2, 2023: Seminars in Oncology
Natasha A Roberts, Elizabeth Ahern, Anita Pelecanos, Harry Gasper, Bryan Chan, Zarnie Lwin
INTRODUCTION: The declaration of the COVID-19 pandemic has resulted in necessary and rapid changes to health service delivery. In the Australian context, it has been broadly identified that these impacts have been felt by health care workers (HCW) providing care. We aimed to capture oncology HCW perceptions of support, stress, personal ability to meet needs and institutional preparedness across longitudinal periods of COVID-19 response in the early stages of the pandemic. METHODS AND MATERIALS: An electronic survey was developed to measure the weekly impacts and distress experienced by HCW during the early phases of the pandemic...
January 27, 2023: Seminars in Oncology
Nerina Denaro, Ornella Garrone, Annamaria Morelli, Benedetta Pellegrino, Marco Carlo Merlano, Denise Vacca, Josie Pearce, Daniele Farci, Antonino Musolino, Mario Scartozzi, Chiara Tommasi, Cinzia Solinas
Glucocorticoids (GCs) are a pharmacological class of drugs widely used in oncology in both supportive and palliative settings. GCs differentially impact organs with immediate and long-term effects; with suppressive effect on the immune system anchoring their use to manage the toxicities of immune checkpoint inhibitors (ICIs). In addition, GCs are often used in the management of symptoms related to cancer or chemotherapy and as adjuvants in the treatment of pain in the management of other. In the palliative setting, GCs, especially administered subcutaneously can be to assist in the control of nausea, dyspnea, asthenia, and anorexia-cachexia syndrome...
January 27, 2023: Seminars in Oncology
Tito Fojo
No abstract text is available yet for this article.
January 26, 2023: Seminars in Oncology
Kathryn J Ruddy, David Zahrieh, Jun He, Blake Waechter, Julianne L Holleran, Lionel D Lewis, Selina Chow, Jan Beumer, Matthias Weiss, Nikolaos Trikalinos, Bryan Faller, Maryam Lustberg, Hope S Rugo, Charles Loprinzi
mTOR inhibitors such as everolimus may cause oral stomatitis, often a dose-limiting toxicity. Prior clinical research has suggested that a dexamethasone mouth rinse might help prevent and/or treat this. Alliance A221701 was a randomized phase III trial of patients initiating 10 mg daily oral everolimus that compared dexamethasone mouthwash taken preventively (initial dexamethasone group) versus therapeutically (initial placebo group) to assess two coprimary endpoints: the incidence of mTOR inhibitor-associated stomatitis (mIAS), and the area under the curve (AUC) of mIAS-associated pain over an 8-week treatment period...
January 17, 2023: Seminars in Oncology
David Smith, Micaela Raices, Federico Cayol, Franco Corvatta, Lucas Caram, Agustín Dietrich
Inflammation plays a key role in malignant tumor progression. Neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and, as such, high isolated pretreatment NLR has been shown in some studies to be associated with worse long-term outcomes. We summarize the data regarding the utility of NLR as a prognosis factor and present results of a single institution study assessing the usefulness of high preoperative NLR as a prognosis factor for patients with successfully resected NSCLC who receive adjuvant cisplatin-based chemotherapy...
December 2022: Seminars in Oncology
Yoshan Moodley, Kumeren Govender, Jacqueline van Wyk, Seren Reddy, Yuming Ning, Steven Wexner, Laura Stopforth, Shona Bhadree, Vasudevan Naidoo, Shakeel Kader, Shalen Cheddie, Alfred I Neugut, Ravi P Kiran
This systematic review was conducted to investigate predictors of treatment refusal in colorectal cancer (CRC) patients. An understanding of these predictors would inform statistical models for the identification of high-risk patients who might benefit from interventions that seek to improve treatment compliance. We performed a search of PubMed and Scopus to identify potentially relevant studies on predictors of treatment refusal in CRC patients that were published between January 1, 2000 and December 31, 2021...
December 2022: Seminars in Oncology
Stefano Testa, Jyoti Kumar, Alex J Goodell, James L Zehnder, Kevin M Alexander, Surbhi Sidana, Sally Arai, Ronald M Witteles, Michaela Liedtke
Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients with MM outside of the transplant setting, and in those with other more indolent PCDs remains elusive...
December 1, 2022: Seminars in Oncology
Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, Gabriele Sorce, Andrea Panunzio, Stefano Tappero, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F Shariat, Markus Graefen, Derya Tilki, Alessandro Antonelli, Marina Kosiba, Luis A Kluth, Andreas Becker, Felix K H Chun, Pierre I Karakiewicz
Multiple systemic immune-oncology (IO) combination therapies have demonstrated overall survival (OS) benefits in metastatic renal clear cell carcinoma (mRCC). However, the magnitude of benefits over time has not been compared in a structured fashion. To assess OS and progression free survival (PFS) efficacy as reflected by hazard ratios [HR]) according to the duration of follow-up over time for each of four IO combination therapies. A systematic PubMed (MEDLINE) literature review was performed (January, 1, 2016 to February, 20, 2022)...
October 2022: Seminars in Oncology
Stefano Cavalieri, Imperia Nuzzolese, Lisa Licitra
The development of deintensified therapies aiming at reducing the treatment-related toxicity while not impairing the outcome is an unmet need in HPV+ oropharyngeal carcinoma patients. Several deintensification approaches have been explored in this setting, including induction chemotherapy with reduced chemoradiation dose in responding pts. The findings of the studies conducted so far show that the available deescalated therapy should be based on the disease risk profile. At present, we still lack robust high level data to infer that the cited interventions are equivalent or superior to standard of care treatments...
October 2022: Seminars in Oncology
Gianluca Ingrosso, Marta Bottero, Carlotta Becherini, Saverio Caini, Emanuele Alì, Andrea Lancia, Piet Ost, Giuseppe Sanguineti, Shankar Siva, Thomas Zilli, Giulio Francolini, Rita Bellavita, Cynthia Aristei, Lorenzo Livi, Beatrice Detti
Prostate cancer is the second most common cause of cancer-related mortality in men. In patients undergoing a failure after radical treatment, one of the therapeutic option is androgen deprivation: despite initial response rates, a progression to a state of castration resistance is observed in most of the patients. In the present article, we conducted a systematic review and meta-analysis of all clinical trials assessing treatment for nmCRPC with next-generation androgen receptor inhibitors. We performed a review and meta-analysis of phase III randomized controlled trials comparing new agents (apalutamide, enzalutamide, darolutamide) with placebo as control arm, in the setting of nmCRPC...
October 2022: Seminars in Oncology
Harshraj Leuva, Mengxi Zhou, Norbert Brau, Sheldon T Brown, Prabhjot Mundi, Ta-Chueh Melody Rosenberg, Carol Luhrs, Susan E Bates, Yeun-Hee Anna Park, Tito Fojo
PURPOSE: Coronavirus disease 2019 (COVID-19) has been a constant health threat since its emergence. Amongst risk factors proposed, a diagnosis of cancer has been worrisome. We report the impact of cancer and other risk factors in US Veterans receiving care at Veterans Administration (VA) Hospitals, their adjusted odds ratio (aOR) for infection and death, and report on the impact of vaccines on the incidence and severity of COVID-19 infections in Veterans without/with cancer. METHODS: We conducted a cohort study of US Veterans without/with cancer by mining VA COVID-19 Shared Data Resource (CSDR) data using the VA Informatics and Computing Infrastructure (VINCI)...
October 2022: Seminars in Oncology
Lorenzo Belluomini, Sara Pilotto, Alice Avancini, Jessica Insolda, Marco Sposito, Jessica Menis, Chiara Ciccarese, Roberto Iacovelli, Miriam Grazia Ferrara, Michele Milella, Emilio Bria, Antonio Rossi
We performed an updated meta-analysis to explore the role of maintenance therapy in SCLC. Clinical trials with randomization to maintenance/consolidation (V) placebo or observation or best supportive care in SCLC, both extended and limited disease were searched from January 2009 to March 2022. The hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence interval (CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies...
September 23, 2022: Seminars in Oncology
Nadejda Baklizi, Musthafa Raswoli, Michala Burges, Daniel C Moreira, Ibrahim Qaddoumi
To assess the frequency of torticollis as a presenting symptom of pediatric CNS tumors and its impact on pre-diagnostic symptom intervals (PSIs) and patient outcomes. We performed a systematic review of studies reporting torticollis in children with various CNS tumors. We searched PubMed for studies published from January 1972 to March 2021 in English. Case reports were included in the analysis if the following criteria were met (1) torticollis was the presenting symptom secondary to a CNS tumor (2) children <18 years of age, (3) underwent imaging intervention and (4) outcome data provided...
September 21, 2022: Seminars in Oncology
Laura Pala, Tommaso De Pas, Fabio Conforti
Immunotherapy with immune-checkpoint inhibitors (ICIs) has revolutionized the landscape of cancer treatment, dramatically improving the prognosis of patients with several solid tumors. Sex and gender are variables that affect immune responses to both foreign and self-antigens and growing preclinical and clinical evidence show that they also affect efficacy and tolerability of anticancer immunotherapy in patients with several advanced solid tumors. Despite such strong biological rationale and available evidence highlighting the need to take into account sex-based differences in the context of both research and clinical practice for anticancer immunotherapy, we described here an impressive under-representation of women enrolled in randomized clinical trials (RCTs) testing such drugs over the last 10 years...
September 20, 2022: Seminars in Oncology
Carlos E Stecca, Marie Alt, Di Maria Jiang, Glaucia Michelis, Nazanin Fallah-Rad, Sharlene Gill, Mary Elliot, Srikala S Sridhar
BACKGROUND: The COVID-19 pandemic has led to significant disruptions across all levels of medical training. International fellows in subspecialty training programs are essential members of the frontline physician workforce, but may face additional and unique challenges as a result of being away from their home country. In this study, we aimed to understand the impact of the COVID-19 pandemic on the wellbeing of international fellows in the Hematology and/or Oncology fellowship program at the PMCC...
September 8, 2022: Seminars in Oncology
Juan Alban, Kathleen Kennedy, Alicia Hulbert, Melani Lighter, Mary Pasquinelli, Israel Rubinstein, Seema Ghelani, Andrew Clayburn, Lawrence E Feldman
Recommending video-assisted thoracic surgery (VATS) over open thoracotomy to patients with early-stage non-small-cell lung cancer (NSCLC) is controversial. Accordingly, we reviewed randomized comparative studies to determine the risks and benefits of VATS lobectomy. Electronic searches on PubMed with standard search terms revealed 97 comparative studies published between 1990 and 2022. Of those, only 5 were randomized controlled clinical trials (RCT) and 1 is still ongoing although initial data has been published as an abstract form...
August 28, 2022: Seminars in Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.